CollPlant Biotechnologies Ltd (CLGN)

Every figure this model derived for CLGN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 28,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 5,591,000 CashAndCashEquivalentsAtCarryingValue 2025-12-31
current assets 6,747,000 AssetsCurrent 2025-12-31
current liabilities 2,672,000 LiabilitiesCurrent 2025-12-31
equity 6,081,000 StockholdersEquity 2025-12-31
ocf -9,419,000 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 2,371,000 Revenues 2025-12-31
sbc 999,000 ShareBasedCompensation 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up CLGN on one particular measure came for.

RatioValue
cash operating margin-403.71
current ratio2.53
current ratio reported2.53
deferred revenue growth-84.54
dilution pct6.54
fcf margin-398.44
growth cv1.81
operating margin-484.31
owner earnings margin-440.57
revenue growth360.39
revenue growth per share332.11
roic-1851.34
rule of 40-123.92
sbc pct revenue42.13

What to be careful about

What this model itself distrusts about CLGN's figures. Written by the derivation as it ran, not added afterwards.